NEW YORK (GenomeWeb News) – The US Food and Drug Administration said yesterday that it has granted BioMérieux's Vitek MS clinical microbiology mass spectrometry system 510(k) de novo clearance.

The system, which uses MALDI-TOF mass spec to identify disease-causing organisms including bacteria and yeast, is the first such platform cleared for clinical use in the US. The Vitek MS identifies microbes by matching the protein profiles of sample organisms generated via MALDI mass spec to profiles contained in a proprietary database.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.